Valuation : Santhera Pharmaceuticals Holding AG

Market Cap 235M 291M 251M 215M 404M 27.82B 406M 2.79B 1.09B 14.04B 1.09B 1.07B 46.56B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 263M 325M 280M 240M 452M 31.09B 453M 3.12B 1.22B 15.7B 1.22B 1.19B 52.04B EV / Sales 2026 *
2.78x
EV / Sales 2027 * 2.22x
Free-Float
81.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.90%
1 week-7.33%
Current month+8.90%
1 month+2.80%
3 months-3.38%
6 months-8.76%
Current year+22.38%
1 week 15.3
Extreme 15.3
16.8
1 month 13.86
Extreme 13.86
17.24
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
25.4
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 2026-07-14
Director of Finance/CFO 51 2025-02-23
Chief Operating Officer 55 2022-08-31
Director TitleAgeSince
Chairman 64 2022-06-29
Director/Board Member 58 2017-04-03
Director/Board Member 47 2023-06-26
Date Insider Type Main position Quantity % Market Cap.
1/22/24 Buy 30,228 0.2396%
7/6/23 Buy 2,000 0.0016%
1/11/22 Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%-7.33%+11.42%+90.37% 291M
-0.80%-2.75%+78.28%+36.19% 366B
+0.11%+1.67%+30.40%-13.48% 70.76B
-1.47%-2.61%+44.69%+148.23% 11.96B
+1.74%+3.38%+4.70%+1.10% 8.72B
0.00%+5.14%-11.65%+3.77% 5B
+2.66%+3.16%-26.37%+23.81% 4.59B
-1.79%-1.23%-26.50%+7.14% 3.16B
-1.04%-4.62%-3.61%+39.76% 2.54B
-5.18%-1.51%-17.37%-1.03% 2.08B
Average -0.67%-0.39%+8.40%+33.59% 47.51B
Weighted average by Cap. -0.62%-1.84%+65.40%+30.20%

Financials

2026 *2027 *
Net sales 94.7M 117M 101M 86.45M 163M 11.2B 163M 1.12B 438M 5.65B 440M 431M 18.75B 116M 143M 123M 105M 199M 13.67B 199M 1.37B 535M 6.9B 537M 525M 22.88B
Net income - -
Net Debt 27.7M 34.29M 29.54M 25.29M 47.64M 3.28B 47.79M 329M 128M 1.65B 129M 126M 5.48B 21.4M 26.49M 22.82M 19.54M 36.8M 2.53B 36.92M 254M 99.06M 1.28B 99.45M 97.28M 4.24B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
26-08-28 CHF 15.42 -0.90% 76,441
26-08-27 CHF 15.56 -0.64% 51,901
26-08-26 CHF 15.66 -0.25% 37,313
26-08-25 CHF 15.70 -1.75% 61,802
26-08-24 CHF 15.98 -3.97% 43,112
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.42CHF
Average target price
27.50CHF
Spread / Average Target
+78.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock